{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:14:16Z","timestamp":1792088056469,"version":"4.4.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,21]]},"DOI":"10.7759\/cureus.95112","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:11:29Z","timestamp":1761113489000},"source":"Crossref","is-referenced-by-count":2,"title":["Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy"],"prefix":"10.7759","author":[{"given":"Max S","family":"Duesberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle cell disease: a review","volume":"328","author":"Kavanagh PL","year":"2022","unstructured":"Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: a review. JAMA. 2022, 328:57-68. 10.1001\/jama.2022.10233","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.016","article-title":"Current and future treatments for sickle cell disease: from hematopoietic stem cell transplantation to in vivo gene therapy","volume":"33","author":"Ball J","year":"2025","unstructured":"Ball J, Bradley A, Le A, Tisdale JF, Uchida N. Current and future treatments for sickle cell disease: from hematopoietic stem cell transplantation to in vivo gene therapy. Mol Ther. 2025, 33:2172-91. 10.1016\/j.ymthe.2025.03.016","journal-title":"Mol Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035237","article-title":"Understanding sickle cell disease: causes, symptoms, and treatment options","volume":"102","author":"Elendu C","year":"2023","unstructured":"Elendu C, Amaechi DC, Alakwe-Ojimba CE, et al.. Understanding sickle cell disease: causes, symptoms, and treatment options. Medicine (Baltimore). 2023, 102:e35237. 10.1097\/MD.0000000000035237","journal-title":"Medicine (Baltimore)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06216-1","article-title":"A review on disease modifying pharmacologic therapies for sickle cell disease","volume":"104","author":"Mahadevia H","year":"2025","unstructured":"Mahadevia H, Ponvilawan B, Madan U, Sharma P, Qasim H, Shrestha A. A review on disease modifying pharmacologic therapies for sickle cell disease. Ann Hematol. 2025, 104:881-93. 10.1007\/s00277-025-06216-1","journal-title":"Ann Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01237-z","article-title":"Advances in the diagnosis and treatment of sickle cell disease","volume":"15","author":"Brandow AM","year":"2022","unstructured":"Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. J Hematol Oncol. 2022, 15:20. 10.1186\/s13045-022-01237-z","journal-title":"J Hematol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2023.0348","article-title":"Red blood cells as therapeutic target to treat sickle cell disease","volume":"40","author":"Bhatt S","year":"2024","unstructured":"Bhatt S, Argueta DA, Gupta K, Kundu S. Red blood cells as therapeutic target to treat sickle cell disease. Antioxid Redox Signal. 2024, 40:1025-49. 10.1089\/ars.2023.0348","journal-title":"Antioxid Redox Signal"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1055540","article-title":"Development of curative therapies for sickle cell disease","volume":"9","author":"Tanhehco YC","year":"2022","unstructured":"Tanhehco YC, Nathu G, Vasovic LV. Development of curative therapies for sickle cell disease. Front Med (Lausanne). 2022, 9:1055540. 10.3389\/fmed.2022.1055540","journal-title":"Front Med (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn BP","year":"2014","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN, et al.. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014, 312:1033-48. 10.1001\/jama.2014.10517","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-066842","article-title":"Health supervision for children and adolescents with sickle cell disease: clinical report","volume":"154","author":"Yates AM","year":"2024","unstructured":"Yates AM, Aygun B, Nuss R, Rogers ZR. Health supervision for children and adolescents with sickle cell disease: clinical report. Pediatrics. 2024, 154:10.1542\/peds.2024-066842","journal-title":"Pediatrics"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.001","article-title":"Advances in the treatment of sickle cell disease","volume":"93","author":"Kapoor S","year":"2018","unstructured":"Kapoor S, Little JA, Pecker LH. Advances in the treatment of sickle cell disease. Mayo Clin Proc. 2018, 93:1810-24. 10.1016\/j.mayocp.2018.08.001","journal-title":"Mayo Clin Proc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.44546","article-title":"Use of disease-modifying treatments in patients with sickle cell disease","volume":"6","author":"Newman TV","year":"2023","unstructured":"Newman TV, Yang J, Suh K, Jonassaint CR, Kane-Gill SL, Novelli EM. Use of disease-modifying treatments in patients with sickle cell disease. JAMA Netw Open. 2023, 6:e2344546. 10.1001\/jamanetworkopen.2023.44546","journal-title":"JAMA Netw Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel FB","year":"2017","unstructured":"Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017, 376:1561-73. 10.1056\/NEJMra1510865","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000486","article-title":"The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally","volume":"2023","author":"Kassim AA","year":"2023","unstructured":"Kassim AA, DeBaun MR. The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally. Hematology Am Soc Hematol Educ Program. 2023, 2023:532-41. 10.1182\/hematology.2023000486","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000821","article-title":"How I treat sickle cell disease with hematopoietic cell transplantation","volume":"134","author":"Stenger EO","year":"2019","unstructured":"Stenger EO, Shenoy S, Krishnamurti L. How I treat sickle cell disease with hematopoietic cell transplantation. Blood. 2019, 134:2249-60. 10.1182\/blood.2019000821","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100868","article-title":"Allogeneic hematopoietic stem cell transplant for sickle cell disease: the why, who, and what","volume":"50","author":"Cimpeanu E","year":"2021","unstructured":"Cimpeanu E, Poplawska M, Jimenez BC, Dutta D, Lim SH. Allogeneic hematopoietic stem cell transplant for sickle cell disease: the why, who, and what. Blood Rev. 2021, 50:100868. 10.1016\/j.blre.2021.100868","journal-title":"Blood Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03662-2","article-title":"Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1\/2 trial","volume":"31","author":"Grimley M","year":"2025","unstructured":"Grimley M, Davies SM, Shrestha A, et al.. Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1\/2 trial. Nat Med. 2025, 31:2204-12. 10.1038\/s41591-025-03662-2","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of lentiGlobin for sickle cell disease","volume":"386","author":"Kanter J","year":"2022","unstructured":"Kanter J, Walters MC, Krishnamurti L, et al.. Biologic and clinical efficacy of lentiGlobin for sickle cell disease. N Engl J Med. 2022, 386:617-28. 10.1056\/NEJMoa2117175","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease","volume":"389","author":"Sharma A","year":"2023","unstructured":"Sharma A, Boelens JJ, Cancio M, et al.. CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease. N Engl J Med. 2023, 389:820-32. 10.1056\/NEJMoa2215643","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042921-021707","article-title":"Diverse approaches to gene therapy of sickle cell disease","volume":"74","author":"White SL","year":"2023","unstructured":"White SL, Hart K, Kohn DB. Diverse approaches to gene therapy of sickle cell disease. Annu Rev Med. 2023, 74:473-87. 10.1146\/annurev-med-042921-021707","journal-title":"Annu Rev Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf2444","article-title":"Development of \u03b2-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease","volume":"13","author":"Lattanzi A","year":"2021","unstructured":"Lattanzi A, Camarena J, Lahiri P, et al.. Development of \u03b2-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Transl Med. 2021, 13:10.1126\/scitranslmed.abf2444","journal-title":"Sci Transl Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000949","article-title":"Lentiviral and genome-editing strategies for the treatment of \u03b2-hemoglobinopathies","volume":"134","author":"Magrin E","year":"2019","unstructured":"Magrin E, Miccio A, Cavazzana M. Lentiviral and genome-editing strategies for the treatment of \u03b2-hemoglobinopathies. Blood. 2019, 134:1203-13. 10.1182\/blood.2019000949","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2021.01.001","article-title":"Hematopoietic-stem-cell-targeted gene-addition and gene-editing strategies for \u03b2-hemoglobinopathies","volume":"28","author":"Drysdale CM","year":"2021","unstructured":"Drysdale CM, Nassehi T, Gamer J, Yapundich M, Tisdale JF, Uchida N. Hematopoietic-stem-cell-targeted gene-addition and gene-editing strategies for \u03b2-hemoglobinopathies. Cell Stem Cell. 2021, 28:191-208. 10.1016\/j.stem.2021.01.001","journal-title":"Cell Stem Cell"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd P","year":"2019","unstructured":"Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019, 14:263-92. 10.1146\/annurev-pathmechdis-012418-012838","journal-title":"Annu Rev Pathol"},{"key":"ref24","article-title":"Sickle cell disease","author":"Bender MA","year":"2023","unstructured":"Bender MA, Carlberg K, Adam MP, et al.. Sickle cell disease. GeneReviews\u00ae [Internet]. University of Washington, Seattle, Seattle (WA); 2023."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00454","article-title":"The red blood cell-inflammation vicious circle in sickle cell disease","volume":"11","author":"Nader E","year":"2020","unstructured":"Nader E, Romana M, Connes P. The red blood cell-inflammation vicious circle in sickle cell disease. Front Immunol. 2020, 11:454. 10.3389\/fimmu.2020.00454","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c200024","article-title":"Vasculopathy in sickle cell disease: from red blood cell sickling to vascular dysfunction","volume":"11","author":"Nader E","year":"2021","unstructured":"Nader E, Conran N, Romana M, Connes P. Vasculopathy in sickle cell disease: from red blood cell sickling to vascular dysfunction. Compr Physiol. 2021, 11:1785-803. 10.1002\/cphy.c200024","journal-title":"Compr Physiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13212","article-title":"Insight into the complex pathophysiology of sickle cell anaemia and possible treatment","volume":"102","author":"Piccin A","year":"2019","unstructured":"Piccin A, Murphy C, Eakins E, et al.. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. Eur J Haematol. 2019, 102:319-30. 10.1111\/ejh.13212","journal-title":"Eur J Haematol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby GA","year":"2021","unstructured":"Newby GA, Yen JS, Woodard KJ, et al.. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature. 2021, 595:295-302. 10.1038\/s41586-021-03609-w","journal-title":"Nature"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0790-y","article-title":"Therapeutic base editing of human hematopoietic stem cells","volume":"26","author":"Zeng J","year":"2020","unstructured":"Zeng J, Wu Y, Ren C, et al.. Therapeutic base editing of human hematopoietic stem cells. Nat Med. 2020, 26:535-41. 10.1038\/s41591-020-0790-y","journal-title":"Nat Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34493-1","article-title":"Base-editing-mediated dissection of a \u03b3-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression","volume":"13","author":"Antoniou P","year":"2022","unstructured":"Antoniou P, Hardouin G, Martinucci P, et al.. Base-editing-mediated dissection of a \u03b3-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression. Nat Commun. 2022, 13:6618. 10.1038\/s41467-022-34493-1","journal-title":"Nat Commun"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.10.018","article-title":"Introducing a hemoglobin G-Makassar variant in HSCs by in\u00a0vivo base editing treats sickle cell disease in mice","volume":"32","author":"Li C","year":"2024","unstructured":"Li C, Georgakopoulou A, Paschoudi K, et al.. Introducing a hemoglobin G-Makassar variant in HSCs by in\u00a0vivo base editing treats sickle cell disease in mice. Mol Ther. 2024, 32:4353-71. 10.1016\/j.ymthe.2024.10.018","journal-title":"Mol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018252","article-title":"In\u00a0vivo HSC prime editing rescues sickle cell disease in a mouse model","volume":"141","author":"Li C","year":"2023","unstructured":"Li C, Georgakopoulou A, Newby GA, et al.. In\u00a0vivo HSC prime editing rescues sickle cell disease in a mouse model. Blood. 2023, 141:2085-99. 10.1182\/blood.2022018252","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162939","article-title":"In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies","volume":"7","author":"Li C","year":"2022","unstructured":"Li C, Georgakopoulou A, Newby GA, et al.. In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies. JCI Insight. 2022, 7:10.1172\/jci.insight.162939","journal-title":"JCI Insight"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.047","article-title":"Genome editing strategies for targeted correction of \u03b2-globin mutation in sickle cell disease: from bench to bedside","volume":"33","author":"Butt H","year":"2025","unstructured":"Butt H, Sathish S, London E, et al.. Genome editing strategies for targeted correction of \u03b2-globin mutation in sickle cell disease: from bench to bedside. Mol Ther. 2025, 33:2154-71. 10.1016\/j.ymthe.2025.03.047","journal-title":"Mol Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-024-10715-5","article-title":"Base editors-mediated gene therapy in hematopoietic stem cells for hematologic diseases","volume":"20","author":"Zhang C","year":"2024","unstructured":"Zhang C, Xu J, Wu Y, Xu C, Xu P. Base editors-mediated gene therapy in hematopoietic stem cells for hematologic diseases. Stem Cell Rev Rep. 2024, 20:1387-405. 10.1007\/s12015-024-10715-5","journal-title":"Stem Cell Rev Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2021.01.025","article-title":"Genome editing approaches to \u03b2-hemoglobinopathies","volume":"182","author":"Brusson M","year":"2021","unstructured":"Brusson M, Miccio A. Genome editing approaches to \u03b2-hemoglobinopathies. Prog Mol Biol Transl Sci. 2021, 182:153-83. 10.1016\/bs.pmbts.2021.01.025","journal-title":"Prog Mol Biol Transl Sci"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119527","article-title":"Precision editing as a therapeutic approach for \u0392-hemoglobinopathies","volume":"24","author":"Paschoudi K","year":"2023","unstructured":"Paschoudi K, Yannaki E, Psatha N. Precision editing as a therapeutic approach for \u0392-hemoglobinopathies. Int J Mol Sci. 2023, 24:10.3390\/ijms24119527","journal-title":"Int J Mol Sci"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1065377","article-title":"Clinical genome editing to treat sickle cell disease-a brief update","volume":"9","author":"Zarghamian P","year":"2022","unstructured":"Zarghamian P, Klermund J, Cathomen T. Clinical genome editing to treat sickle cell disease-a brief update. Front Med (Lausanne). 2022, 9:1065377. 10.3389\/fmed.2022.1065377","journal-title":"Front Med (Lausanne)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.10.008","article-title":"Optimization of CRISPR\/Cas9 delivery to human hematopoietic stem and progenitor cells for therapeutic genomic rearrangements","volume":"27","author":"Lattanzi A","year":"2019","unstructured":"Lattanzi A, Meneghini V, Pavani G, et al.. Optimization of CRISPR\/Cas9 delivery to human hematopoietic stem and progenitor cells for therapeutic genomic rearrangements. Mol Ther. 2019, 27:137-50. 10.1016\/j.ymthe.2018.10.008","journal-title":"Mol Ther"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz475","article-title":"Highly efficient editing of the\u00a0\u03b2-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease","volume":"47","author":"Park SH","year":"2019","unstructured":"Park SH, Lee CM, Dever DP, et al.. Highly efficient editing of the\u00a0\u03b2-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. Nucleic Acids Res. 2019, 47:7955-72. 10.1093\/nar\/gkz475","journal-title":"Nucleic Acids Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.147480","article-title":"CRISPR\/Cas9-based gene-editing technology for sickle cell disease","volume":"874","author":"Ma L","year":"2023","unstructured":"Ma L, Yang S, Peng Q, Zhang J, Zhang J. CRISPR\/Cas9-based gene-editing technology for sickle cell disease. Gene. 2023, 874:147480. 10.1016\/j.gene.2023.147480","journal-title":"Gene"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.07.015","article-title":"Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responses","volume":"32","author":"Frati G","year":"2024","unstructured":"Frati G, Brusson M, Sartre G, et al.. Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responses. Mol Ther. 2024, 32:4337-52. 10.1016\/j.ymthe.2024.07.015","journal-title":"Mol Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2025.103513","article-title":"Therapeutic promise of CRISPR-Cas9 gene editing in sickle cell disease and \u03b2-thalassemia: a current review","volume":"73","author":"Almasoudi HH","year":"2025","unstructured":"Almasoudi HH. Therapeutic promise of CRISPR-Cas9 gene editing in sickle cell disease and \u03b2-thalassemia: a current review. Curr Res Transl Med. 2025, 73:103513. 10.1016\/j.retram.2025.103513","journal-title":"Curr Res Transl Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.848261","article-title":"Gene editing for inherited red blood cell diseases","volume":"13","author":"Quintana-Bustamante O","year":"2022","unstructured":"Quintana-Bustamante O, Fa\u00f1anas-Baquero S, Dessy-Rodriguez M, Ojeda-P\u00e9rez I, Segovia JC. Gene editing for inherited red blood cell diseases. Front Physiol. 2022, 13:848261. 10.3389\/fphys.2022.848261","journal-title":"Front Physiol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/nature20134","article-title":"CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells","volume":"539","author":"Dever DP","year":"2016","unstructured":"Dever DP, Bak RO, Reinisch A, et al.. CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells. Nature. 2016, 539:384-9. 10.1038\/nature20134","journal-title":"Nature"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm9106","article-title":"Precise CRISPR-Cas-mediated gene repair with minimal off-target and unintended on-target mutations in human hematopoietic stem cells","volume":"8","author":"Tran NT","year":"2022","unstructured":"Tran NT, Danner E, Li X, et al.. Precise CRISPR-Cas-mediated gene repair with minimal off-target and unintended on-target mutations in human hematopoietic stem cells. Sci Adv. 2022, 8:eabm9106. 10.1126\/sciadv.abm9106","journal-title":"Sci Adv"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul H","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD, et al.. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021, 384:252-60. 10.1056\/NEJMoa2031054","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.07.022","article-title":"Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34(+) cell therapy to induce fetal hemoglobin for sickle cell disease","volume":"32","author":"Katta V","year":"2024","unstructured":"Katta V, O'Keefe K, Li Y, et al.. Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34(+) cell therapy to induce fetal hemoglobin for sickle cell disease. Mol Ther. 2024, 32:3433-52. 10.1016\/j.ymthe.2024.07.022","journal-title":"Mol Ther"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick EB","year":"2021","unstructured":"Esrick EB, Lehmann LE, Biffi A, et al.. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N Engl J Med. 2021, 384:205-15. 10.1056\/NEJMoa2029392","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000867","article-title":"Gene therapy for sickle cell disease and thalassemia","volume":"32","author":"Scaramellini N","year":"2025","unstructured":"Scaramellini N, Panzieri DL, Cappellini MD. Gene therapy for sickle cell disease and thalassemia. Curr Opin Hematol. 2025, 32:120-9. 10.1097\/MOH.0000000000000867","journal-title":"Curr Opin Hematol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02517-4","article-title":"Base editing boosts hemoglobin in sickle cell disease","volume":"42","year":"2024","unstructured":"Base editing boosts hemoglobin in sickle cell disease. Nat Biotechnol. 2024, 42.1759. 10.1038\/s41587-024-02517-4","journal-title":"Nat Biotechnol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58321-4","article-title":"Severe inflammation and lineage skewing are associated with poor engraftment of engineered hematopoietic stem cells in patients with sickle cell disease","volume":"16","author":"Sobrino S","year":"2025","unstructured":"Sobrino S, Joseph L, Magrin E, et al.. Severe inflammation and lineage skewing are associated with poor engraftment of engineered hematopoietic stem cells in patients with sickle cell disease. Nat Commun. 2025, 16:3137. 10.1038\/s41467-025-58321-4","journal-title":"Nat Commun"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.03.005","article-title":"Autologous gene therapy for hemoglobinopathies: from bench to patient's bedside","volume":"32","author":"Locatelli F","year":"2024","unstructured":"Locatelli F, Cavazzana M, Frangoul H, Fuente J, Algeri M, Meisel R. Autologous gene therapy for hemoglobinopathies: from bench to patient's bedside. Mol Ther. 2024, 32:1202-18. 10.1016\/j.ymthe.2024.03.005","journal-title":"Mol Ther"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.08.019","article-title":"Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease","volume":"30","author":"Ramadier S","year":"2022","unstructured":"Ramadier S, Chalumeau A, Felix T, et al.. Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease. Mol Ther. 2022, 30:145-63. 10.1016\/j.ymthe.2021.08.019","journal-title":"Mol Ther"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666210527092456","article-title":"Gene therapy as the new frontier for sickle cell disease","volume":"29","author":"Garg H","year":"2022","unstructured":"Garg H, Tatiossian KJ, Peppel K, Kato GJ, Herzog E. Gene therapy as the new frontier for sickle cell disease. Curr Med Chem. 2022, 29:453-66. 10.2174\/0929867328666210527092456","journal-title":"Curr Med Chem"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddz172","article-title":"Gene therapy of hemoglobinopathies: progress and future challenges","volume":"28","author":"Ikawa Y","year":"2019","unstructured":"Ikawa Y, Miccio A, Magrin E, Kwiatkowski JL, Rivella S, Cavazzana M. Gene therapy of hemoglobinopathies: progress and future challenges. Hum Mol Genet. 2019, 28:R24-30. 10.1093\/hmg\/ddz172","journal-title":"Hum Mol Genet"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01650-w","article-title":"Long-term outcomes of lentiviral gene therapy for the \u03b2-hemoglobinopathies: the HGB-205 trial","volume":"28","author":"Magrin E","year":"2022","unstructured":"Magrin E, Semeraro M, Hebert N, et al.. Long-term outcomes of lentiviral gene therapy for the \u03b2-hemoglobinopathies: the HGB-205 trial. Nat Med. 2022, 28:81-8. 10.1038\/s41591-021-01650-w","journal-title":"Nat Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111843","article-title":"Hematopoietic stem cell gene-addition\/editing therapy in sickle cell disease","volume":"11","author":"Germino-Watnick P","year":"2022","unstructured":"Germino-Watnick P, Hinds M, Le A, Chu R, Liu X, Uchida N. Hematopoietic stem cell gene-addition\/editing therapy in sickle cell disease. Cells. 2022, 11:10.3390\/cells11111843","journal-title":"Cells"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study","volume":"98","author":"Kanter J","year":"2023","unstructured":"Kanter J, Thompson AA, Pierciey FJ Jr, et al.. Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study. Am J Hematol. 2023, 98:11-22. 10.1002\/ajh.26741","journal-title":"Am J Hematol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal S","year":"2022","unstructured":"Goyal S, Tisdale J, Schmidt M, et al.. Acute myeloid leukemia case after gene therapy for sickle cell disease. N Engl J Med. 2022, 386:138-47. 10.1056\/NEJMoa2109167","journal-title":"N Engl J Med"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul H","year":"2024","unstructured":"Frangoul H, Locatelli F, Sharma A, et al.. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. 2024, 390:1649-62. 10.1056\/NEJMoa2309676","journal-title":"N Engl J Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2399134","article-title":"An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia","volume":"24","author":"Handgretinger R","year":"2024","unstructured":"Handgretinger R, Mezger M. An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia. Expert Opin Biol Ther. 2024, 24:883-8. 10.1080\/14712598.2024.2399134","journal-title":"Expert Opin Biol Ther"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.944204","article-title":"First regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent \u03b2-thalassemia","volume":"30","author":"Parums DV","year":"2024","unstructured":"Parums DV. First regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent \u03b2-thalassemia. Med Sci Monit. 2024, 30:e944204. 10.12659\/MSM.944204","journal-title":"Med Sci Monit"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2021.09.001","article-title":"Society for Maternal-Fetal Medicine special statement: beyond the scalpel: in utero fetal gene therapy and curative medicine","volume":"225","author":"Shanahan MA","year":"2021","unstructured":"Shanahan MA, Aagaard KM, McCullough LB, Chervenak FA, Shamshirsaz AA. Society for Maternal-Fetal Medicine special statement: beyond the scalpel: in utero fetal gene therapy and curative medicine. Am J Obstet Gynecol. 2021, 225:B9-B18. 10.1016\/j.ajog.2021.09.001","journal-title":"Am J Obstet Gynecol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.107","article-title":"Gene editing of human hematopoietic stem and progenitor cells: promise and potential hurdles","volume":"27","author":"Yu KR","year":"2016","unstructured":"Yu KR, Natanson H, Dunbar CE. Gene editing of human hematopoietic stem and progenitor cells: promise and potential hurdles. Hum Gene Ther. 2016, 27:729-40. 10.1089\/hum.2016.107","journal-title":"Hum Gene Ther"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1381172","article-title":"Navigating equity in global access to genome therapy expanding access to potentially transformative therapies and benefiting those in need requires global policy changes","volume":"15","author":"Lee TL","year":"2024","unstructured":"Lee TL, Sawai T. Navigating equity in global access to genome therapy expanding access to potentially transformative therapies and benefiting those in need requires global policy changes. Front Genet. 2024, 15:1381172. 10.3389\/fgene.2024.1381172","journal-title":"Front Genet"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01236-y","article-title":"CRISPR-based therapeutic genome editing for inherited blood disorders","author":"Levesque S","year":"2025","unstructured":"Levesque S, Bauer DE. CRISPR-based therapeutic genome editing for inherited blood disorders. Nat Rev Drug Discov. 2025, 10.1038\/s41573-025-01236-y","journal-title":"Nat Rev Drug Discov"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil JA","year":"2017","unstructured":"Ribeil JA, Hacein-Bey-Abina S, Payen E, et al.. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017, 376:848-55. 10.1056\/NEJMoa1609677","journal-title":"N Engl J Med"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003776","article-title":"Gene therapy for sickle cell disease: moving from the bench to the bedside","volume":"138","author":"Abraham AA","year":"2021","unstructured":"Abraham AA, Tisdale JF. Gene therapy for sickle cell disease: moving from the bench to the bedside. Blood. 2021, 138:932-41. 10.1182\/blood.2019003776","journal-title":"Blood"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dead167","article-title":"Heritable genome editing: ethical aspects of a developing domain","volume":"38","author":"Segers S","year":"2023","unstructured":"Segers S. Heritable genome editing: ethical aspects of a developing domain. Hum Reprod. 2023, 38:2055-61. 10.1093\/humrep\/dead167","journal-title":"Hum Reprod"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2020.12.008","article-title":"Making sense of heritable human genome editing: scientific and ethical considerations","volume":"182","author":"Greenfield A","year":"2021","unstructured":"Greenfield A. Making sense of heritable human genome editing: scientific and ethical considerations. Prog Mol Biol Transl Sci. 2021, 182:1-28. 10.1016\/bs.pmbts.2020.12.008","journal-title":"Prog Mol Biol Transl Sci"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0409-6","article-title":"A CRISPR focus on attitudes and beliefs toward somatic genome editing from stakeholders within the sickle cell disease community","volume":"21","author":"Persaud A","year":"2019","unstructured":"Persaud A, Desine S, Blizinsky K, Bonham VL. A CRISPR focus on attitudes and beliefs toward somatic genome editing from stakeholders within the sickle cell disease community. Genet Med. 2019, 21:1726-34. 10.1038\/s41436-018-0409-6","journal-title":"Genet Med"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0098","article-title":"Improving access to gene therapies: a holistic view of current challenges and future policy solutions in the United States","volume":"13","author":"Wagner TD","year":"2024","unstructured":"Wagner TD, Buelt L, Westrich K, Campbell JD. Improving access to gene therapies: a holistic view of current challenges and future policy solutions in the United States. J Comp Eff Res. 2024, 13:e240098. 10.57264\/cer-2024-0098","journal-title":"J Comp Eff Res"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-023-00429-7","article-title":"Looking ahead: ethical and social challenges of somatic gene therapy for sickle cell disease in Africa","volume":"31","author":"Munung NS","year":"2024","unstructured":"Munung NS, Nnodu OE, Moru PO, Kalu AA, Impouma B, Treadwell MJ, Wonkam A. Looking ahead: ethical and social challenges of somatic gene therapy for sickle cell disease in Africa. Gene Ther. 2024, 31:202-8. 10.1038\/s41434-023-00429-7","journal-title":"Gene Ther"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.7140","article-title":"A budget impact analysis of gene therapy for sickle cell disease: the Medicaid perspective","volume":"175","author":"DeMartino P","year":"2021","unstructured":"DeMartino P, Haag MB, Hersh AR, Caughey AB, Roth JA. A budget impact analysis of gene therapy for sickle cell disease: the Medicaid perspective. JAMA Pediatr. 2021, 175:617-23. 10.1001\/jamapediatrics.2020.7140","journal-title":"JAMA Pediatr"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.01.008","article-title":"Sickle cell disease gene therapy drug expenses and reimbursement: a litmus test for commercial pricing strategy and patient access for curative therapies","volume":"27","author":"Grilley BJ","year":"2025","unstructured":"Grilley BJ, Hume A, Galipeau J. Sickle cell disease gene therapy drug expenses and reimbursement: a litmus test for commercial pricing strategy and patient access for curative therapies. Cytotherapy. 2025, 27:567-70. 10.1016\/j.jcyt.2025.01.008","journal-title":"Cytotherapy"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13612","article-title":"Current state of gene therapy in sickle cell disease","volume":"119","author":"Tang MS","year":"2024","unstructured":"Tang MS, Shan H. Current state of gene therapy in sickle cell disease. Vox Sang. 2024, 119:521-8. 10.1111\/vox.13612","journal-title":"Vox Sang"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07800-7","article-title":"A roadmap for affordable genetic medicines","volume":"634","author":"Kliegman M","year":"2024","unstructured":"Kliegman M, Zaghlula M, Abrahamson S, Esensten JH, Wilson RC, Urnov FD, Doudna JA. A roadmap for affordable genetic medicines. Nature. 2024, 634:307-14. 10.1038\/s41586-024-07800-7","journal-title":"Nature"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.08.002","article-title":"Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa","volume":"60","author":"Ally M","year":"2023","unstructured":"Ally M, Balandya E. Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa. Semin Hematol. 2023, 60:192-9. 10.1053\/j.seminhematol.2023.08.002","journal-title":"Semin Hematol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2021-323633","article-title":"Sickle cell disease in children: an update of the evidence in low- and middle-income settings","volume":"108","author":"Odame I","year":"2023","unstructured":"Odame I. Sickle cell disease in children: an update of the evidence in low- and middle-income settings. Arch Dis Child. 2023, 108:108-14. 10.1136\/archdischild-2021-323633","journal-title":"Arch Dis Child"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53121-0","article-title":"The value-based price of transformative gene therapy for sickle cell disease: a modeling analysis","volume":"14","author":"Morgan G","year":"2024","unstructured":"Morgan G, Back E, Besser M, Hallett TB, Guzauskas GF. The value-based price of transformative gene therapy for sickle cell disease: a modeling analysis. Sci Rep. 2024, 14:2739. 10.1038\/s41598-024-53121-0","journal-title":"Sci Rep"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1111\/ahg.12558","article-title":"The dawn of a cure for sickle cell disease through CRISPR-based treatment: a critical test of equity in public health genomics","volume":"89","author":"Mboowa G","year":"2025","unstructured":"Mboowa G, Sserwadda I, Kanyerezi S, Tukwasibwe S, Kidenya B. The dawn of a cure for sickle cell disease through CRISPR-based treatment: a critical test of equity in public health genomics. Ann Hum Genet. 2025, 89:188-94. 10.1111\/ahg.12558","journal-title":"Ann Hum Genet"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000550","article-title":"Transfusions, disease-modifying treatments, and curative therapies for sickle cell anemia in Africa: where are we now?","volume":"2024","author":"Odame I","year":"2024","unstructured":"Odame I, Bazuaye GN. Transfusions, disease-modifying treatments, and curative therapies for sickle cell anemia in Africa: where are we now?. Hematology Am Soc Hematol Educ Program. 2024, 2024:234-9. 10.1182\/hematology.2024000550","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00284-4","article-title":"Towards access for all: 1st working group report for the Global Gene Therapy Initiative (GGTI)","volume":"30","author":"Adair JE","year":"2023","unstructured":"Adair JE, Androski L, Bayigga L, et al.. Towards access for all: 1st working group report for the Global Gene Therapy Initiative (GGTI). Gene Ther. 2023, 30:216-21. 10.1038\/s41434-021-00284-4","journal-title":"Gene Ther"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-041817-125507","article-title":"Emerging genetic therapy for sickle cell disease","volume":"70","author":"Orkin SH","year":"2019","unstructured":"Orkin SH, Bauer DE. Emerging genetic therapy for sickle cell disease. Annu Rev Med. 2019, 70:257-71. 10.1146\/annurev-med-041817-125507","journal-title":"Annu Rev Med"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.11.006","article-title":"Gene therapy for sickle cell disease: recent advances, clinical trials and future directions","volume":"27","author":"Ballantine J","year":"2025","unstructured":"Ballantine J, Tisdale JF. Gene therapy for sickle cell disease: recent advances, clinical trials and future directions. Cytotherapy. 2025, 27:826-34. 10.1016\/j.jcyt.2024.11.006","journal-title":"Cytotherapy"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.29443","article-title":"Assessing psychosocial risk and resilience to support readiness for gene therapy in sickle cell disease: a consensus statement","volume":"7","author":"Hardy SJ","year":"2024","unstructured":"Hardy SJ, Crosby LE, Porter JS, et al.. Assessing psychosocial risk and resilience to support readiness for gene therapy in sickle cell disease: a consensus statement. JAMA Netw Open. 2024, 7:e2429443. 10.1001\/jamanetworkopen.2024.29443","journal-title":"JAMA Netw Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/416961-emerging-therapies-for-sickle-cell-disease-from-symptom-management-to-curative-gene-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:11:30Z","timestamp":1761113490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/416961-emerging-therapies-for-sickle-cell-disease-from-symptom-management-to-curative-gene-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":87,"URL":"https:\/\/doi.org\/10.7759\/cureus.95112","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,21]]}}}